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Putting two and two together: crystal structure of the
FGF–receptor complex
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The recently determined crystal structure of an
FGF–receptor complex reveals a surprising architecture
and a novel mode of receptor dimerization. The structure
also elucidates the role of heparan sulfate proteoglycans
in receptor activation, showing significant differences from
previously proposed models.
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A heparin string with fibroblast growth factor (FGF)
beads, heparin glue between FGF monomers, or heparin
glue between FGF and its receptor? Two receptor mol-
ecules brought together by a single FGF monomer, by an
FGF dimer, or in higher order aggregates? All these
models and variations on them have been proposed to
explain the molecular mechanism for the heparin depen-
dence of FGF-induced receptor activation. With the
crystal structure of the complex between FGF and a
natural isoform of its receptor ectodomain, these questions
have finally been answered, and the answers are surprising
and unexpected [1].
FGFs have important roles in a variety of biological
processes such as cell growth, differentiation, angiogenesis
and wound healing. They are also implicated in a number
of pathological processes such as diabetic retinopathy,
rheumatoid disease and tumor growth, making them prime
targets for the development of treatments against these
diseases. The cellular receptors for FGFs are receptor
tyrosine kinases (RTKs), so named because of their intra-
cellular tyrosine kinase domain. RTKs are activated
through ligand-induced dimerization, which brings
together the cytoplasmic domains and results in the
transphosphorylation of tyrosine residues in the intracellu-
lar regions [2]. Subsequent events include phosphorylation
of ‘adaptor’ modules, which then recruit additional compo-
nents of the intracellular signaling pathway (reviewed in
[3]). Recent crystallographic studies have revealed the
mechanisms for some of these early intracellular processes
at the atomic level, and this knowledge has been applied
in the design of specific small-molecule inhibitors [4,5]. 
In contrast to the wealth of structural information avail-
able for the cytoplasmic domains, until recently very little
was known about the molecular details of the extracellular
events that trigger the entire cascade [6]. FGFs exist as
monomers in solution, and crystal structures of the free
and heparin-bound growth factor have been determined
(reviewed in [7,8]). FGFs are able to form 1:1 complexes
with their high-affinity receptors. These complexes are
inactive, however, because like some other important
RTK ligands, such as hepatocyte growth factor and trans-
forming growth factor β, heparan-sulfate-containing pro-
teoglycans are required for receptor activation [9]. The
minimum length of heparin-like molecules that will
support the formation of active complexes is eight saccha-
rides, and maximum activity is reached with twelve [10].
Crystal structures of complexes between FGF and various
heparin-like molecules have identified a number of
heparin-binding sites on the surface of FGF, and mutage-
nesis studies have shown that two of these, a high-affinity
and a low-affinity site, are physiologically important
(reviewed in [7]). An important question relates to the
composition of the active complex. Unlike many homo-
dimeric RTK ligands, FGFs are monomeric molecules,
raising questions about the molecular mechanism of
receptor dimerization. In one proposed model, consistent
with mutagenesis studies that revealed two separate
receptor-binding sites on FGF [11], a single FGF
monomer interacts with two copies of the receptor. The
resulting complex was therefore speculated to have a 1:2
stoichiometry, much like that observed for the interaction
between human growth hormone and its receptor [12].
Other proposals were based on a 2:2 composition
(Figure 1), with heparan sulfate molecules either bridging
between FGF monomers (Figure 1a), as observed in some
of the crystal structures, or between FGF and the receptor
(Figure 1b). Finally, as long segments of heparin can bind
to many FGF molecules simultaneously (Figure 1c), pos-
sibly in a ‘beads-on-a-string’ fashion [13], the possibility
existed that active complexes actually consist of much
larger ligand–receptor aggregates [9]. 
The recently determined crystal structure of the complex
between FGF2 and a naturally occurring variant of FGF
receptor 1 (FGFR1) resolves all these ambiguities, reveals
a novel dimerization mode, and suggests a convincing
model for the role of heparin in the stabilization of the
active signaling complex (Figure 2) [1]. The extracellular
portion of cell-bound FGF receptors usually consists of
three immunoglobulin-like domains, but in this study a
receptor isoform was used containing only domains 2
and 3. The ligand binding and specificity functionality is
conferred by domains 2 and 3, however, so the complex
observed has general biological relevance for the entire
FGF family.
The complex is assembled from two FGF2 molecules and
two copies of FGFR1 (Figure 2). Each copy of the ligand
uses the high-affinity site identified by mutagenesis [11]
in an intimate interaction with one of the FGFR1 mol-
ecules, burying a total of no less than 2700 Å2 in this
primary interface and effectively dividing the complex
into two 1:1 halves. The two 1:1 portions are assembled in
a back-to-back fashion to form the complete 2:2 complex
through an interface in which only ~1000 Å2 accessible
surface is buried. No direct ligand–ligand contacts are
found in this secondary interface, or in fact anywhere in
the complex. Instead, the interactions here include a
patch of ~300 Å2 between the two receptors, while the
remaining 700 Å2 are accounted for by interactions
between FGF and the receptor from the other 1:1
portion. The relative sizes of the two interfaces explain
nicely the existence of 1:1 complexes in solution; forma-
tion of the 2:2 complex observed here despite the
absence of heparin-like molecules was possible presum-
ably because of the high protein concentration used in
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Figure 1
Cartoons comparing various previously
proposed models for the active FGF–receptor
complex with the assembly proposed on the
basis of the crystal structure. In all panels, the
membrane is shown at the bottom, FGF is
rendered as a yellow circle, the receptor
domains as green and blue ovals, and heparin
as a red bar. (a) Model based on the heparin-
mediated FGF dimer observed by DiGabriele
et al. [20]. Two FGF molecules bind to
opposite sides of heparin and interact with
two copies of the receptor in a twofold
symmetric complex. In this model, heparin-
mediated receptor–receptor interactions can
also occur. (b) A model based on the crystal
structure of the complex formed between
interleukin-1 and its receptor [21]. In an
overall twofold symmetric complex, heparin
binds in the FGF–receptor interface. Note that
the binding site includes portions of all three
domains of the receptor. (c) A model
following the suggestion of Venkataraman et
al. [13]. FGF molecules bind side-by-side to
the same face of heparin, and two receptors
bind to the opposite face. Addition of further
1:1 complexes leads to ‘beads-on-a-string’.
(d) The signaling complex based on the
crystal structure. A heparin dodecasaccharide
fills a positively charged groove, interacting
with both copies of FGF as well as with both
receptor molecules. 
Structure
(a) (b) (c) (d)
Figure 2
Structure of the complex between FGF2 and
domains 2 and 3 of FGF receptor 1, in two
views related by a 90° rotation about a vertical
axis. Two molecules of FGF (in yellow) are
assembled with two copies of the receptor
(domain 2 in green and domain 3 in blue) to
form a signaling complex with a 2:2
composition. One disordered loop is shown
as a dotted line. (This figure was reproduced
from [1] with permission.)
the crystallization conditions (and stabilization provided
by the crystalline environment). 
Even though heparin was not included in this study, the
structure provides a highly satisfying explanation for all
the experimental evidence pertaining to heparin binding
(Figure 3). A prominent groove is evident at the ‘top’ face
of the complex distal to the membrane, sandwiched by
the two copies of receptor domain 2 and reaching the ‘top’
surface of the FGF molecules at either side (Figures 3a,b).
In the center, the groove is a deep canyon lined by the
positively charged residues from receptor domain 2 that
have been identified as important for heparin binding. At
either end, the groove traverses the low-affinity heparin-
binding site in the ligand and ends in the high-affinity site
on each FGF molecule. In the crystal structure, sulfate
molecules from the crystallization buffer are bound at
various places in this groove, supporting the notion that
this represents the relevant heparin-binding site. The
dimensions of the groove are such that an octasaccharide
can just span the length between the low-affinity sites,
explaining why octasaccharides are the shortest biologi-
cally active heparin mimics, whereas maximally active
dodecasaccharides would also reach the high-affinity sites.
Therefore, the mechanism of receptor activation by
heparan sulfate proteoglycans appears to lie in the stabi-
lization of the active 2:2 complex through a specific cross-
link connecting all four components in the assembly.
Furthermore, as activity does not increase further upon
increasing the saccharide length beyond twelve units, the
signaling species is most likely to be the dimer observed
in the structure, and not some higher order oligomeriza-
tion state. In other words, the active FGF–receptor
complex turns out to resemble a pendant on a chain rather
than beads on a string.
One further novel feature of this complex is its mode of
receptor dimerization. In all other complexes that have
been structurally characterized, the receptor molecules are
dimerized or oligomerized around a central ligand, the sym-
metry of which often (but not always) matches the overall
symmetry of the complex. For example, in the only two
other known crystal structures of RTK binding domains in
complex with their ligands (vascular endothelial growth
factor and nerve growth factor) [14,15], the ligands are
twofold symmetric molecules that are sandwiched between
two receptors which bind at twofold symmetrical binding
sites (Figures 4a,b). In contrast, in the FGF2–FGFR1
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Figure 3
The proposed heparin-binding groove. (a) The molecular surface
viewed from the top relative to Figure 2. The color scheme is as
described in Figure 2; the sidechains of heparin-binding residues are
shown in ball-and-stick rendering. (b) Charge distribution of the
surface shown in (a), with blue and red showing positive and negative
electrostatic potential, respectively. A dodecasaccharide is modeled
into the heparin-binding groove. (c) The molecular surface color-coded
and viewed as in Figure 2. The modeled dodecasaccharide is visible
through a transparent domain 2 surface. (This figure was reproduced
from [1] with permission.)
(a)
(b)
(c)
complex the two ligand molecules reside at the periphery
of the assembly, without direct ligand–ligand interactions.
As described above, receptor dimerization is accomplished
by bringing together stable 1:1 complexes through weak
receptor–receptor interactions and the secondary receptor-
binding site on FGF2. The result is a unique overall assem-
bly of the active complex. 
An important remaining question is whether the precise
disposition of the two copies of domain 3 in the complex is
important for controlling the precise alignment of the
cytoplasmic tyrosine kinase domains, and therefore for sig-
naling. It is difficult to speculate on this point in the
absence of structures of other complete RTK complexes,
but affirming evidence is accumulating for a different
receptor superfamily, the hematopoietic receptors.
Hematopoietic receptors do not contain a cytoplasmic
tyrosine kinase domain, but upon activation recruit spe-
cific tyrosine kinases to their intracellular domains. In the
complex between human growth hormone and its receptor
[12], the two copies of the receptor are in intimate and
apparently specific contact through their receptor ‘stems’,
a short distance before the transmembrane segment
(Figure 4c). For a closely related complex between human
growth hormone and the prolactin receptor, specific recep-
tor–receptor interactions are predicted in the same general
region but with a distinct orientation of the stems [16].
Surprisingly, a third complex in this superfamily, that
between erythropoietin and its receptor [17], revealed an
almost complete lack of direct receptor–receptor contacts
(Figure 4d); yet, comparisons to receptor complexes with
active and inactive peptide erythropoietin mimics [18,19]
suggested that the precise orientation was crucial for effi-
cient signaling. In light of these structures, it seems rea-
sonable to propose that the observed domain alignment is
also important for activity of the FGF receptor.
In just two years we have learned much about the struc-
tural basis for the molecular mechanisms of assembly of
active receptor tyrosine kinase complexes. The two com-
plexes of the related cystine knot growth factors, vascular
endothelial growth factor and nerve growth factor, showed
surprising differences. Furthermore, the first complete
ligand–RTK interaction seen in the FGF2–FGFR1
complex reveals a completely unanticipated architecture
and a novel dimerization mechanism. Clearly, we can look
forward to many more surprises as additional structures of
members of this superfamily are determined.
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(yellow) and its receptor (green and blue). 
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